Designing vaccine candidates against dengue virus by in silico studies on structural and nonstructural domains.
Dengue vaccines
Dengue virus
Docking
Immunity
Molecular dynamics simulation
Journal
Molecular and cellular probes
ISSN: 1096-1194
Titre abrégé: Mol Cell Probes
Pays: England
ID NLM: 8709751
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
14
01
2022
revised:
06
04
2022
accepted:
18
04
2022
pubmed:
25
4
2022
medline:
10
5
2022
entrez:
24
4
2022
Statut:
ppublish
Résumé
One-third of the world's population is at risk of Dengue infection. Envelope domain 3 (EDIII) and nonstructural protein1 (NS1) proteins as the potent antigenicity regions for humoral immunity in addition to the bc loop region as a completely conserved region have been used for designing protective vaccines. We aimed to design vaccine candidates according to the bc loop, EDIII, and NS1 regions of Dengue serotype2 to be used as vaccine candidates for all serotypes of Dengue virus especially serotype 2. Firstly the bc loop region with EDII fragments at both ends as well as EDIII and NS1 regions were used which were linked with the GGGGS linker to the bc loop region. In two other strategies, the bc loop with EDII and NS1 fragments at both ends was used to increase its structural stability. Tertiary structure prediction and validation of vaccine constructs indicated that all vaccine constructs were modeled with high quality and stable structure during molecular dynamics simulation. B cell epitope mapping by Bepipred and ElliPro methods confirmed the existence of high potent epitopes in the bc loop, EDIII, and NS1 regions in both linear and conformational B cell epitopes. Furthermore, molecular docking for the bc loop region demonstrated that all designed vaccines have a higher affinity to interact with 1C19 monoclonal antibody than only the bc loop region or bc loop epitope in the protein EII. Our data of in silico studies indicated that the designed vaccines could effectively induce humoral immunity against four dengue serotypes.
Identifiants
pubmed: 35461964
pii: S0890-8508(22)00029-9
doi: 10.1016/j.mcp.2022.101818
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Epitopes, B-Lymphocyte
0
Vaccines
0
Viral Envelope Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
101818Informations de copyright
Copyright © 2022. Published by Elsevier Ltd.